Envista Holdings Co. (NYSE:NVST – Get Free Report) has been assigned an average recommendation of “Hold” from the fifteen analysts that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and three have issued a buy rating on the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $20.71.
Several brokerages have weighed in on NVST. Leerink Partnrs raised Envista from a “strong sell” rating to a “hold” rating in a report on Thursday, October 31st. Wells Fargo & Company started coverage on shares of Envista in a research note on Tuesday, October 8th. They issued an “equal weight” rating and a $20.00 target price for the company. Robert W. Baird upped their price target on shares of Envista from $17.00 to $22.00 and gave the company a “neutral” rating in a research note on Thursday, October 31st. Stifel Nicolaus lifted their price objective on shares of Envista from $18.00 to $21.00 and gave the stock a “buy” rating in a research note on Wednesday, October 23rd. Finally, Needham & Company LLC reissued a “hold” rating on shares of Envista in a research report on Thursday, October 31st.
View Our Latest Stock Analysis on Envista
Envista Price Performance
Envista (NYSE:NVST – Get Free Report) last issued its quarterly earnings data on Wednesday, October 30th. The company reported $0.12 EPS for the quarter, beating the consensus estimate of $0.09 by $0.03. Envista had a positive return on equity of 3.76% and a negative net margin of 53.42%. The firm had revenue of $601.00 million during the quarter, compared to analyst estimates of $590.34 million. During the same quarter in the prior year, the business posted $0.43 EPS. The business’s revenue for the quarter was down 4.8% compared to the same quarter last year. As a group, analysts predict that Envista will post 0.71 earnings per share for the current fiscal year.
Insiders Place Their Bets
In related news, CFO Eric D. Hammes purchased 24,532 shares of the firm’s stock in a transaction on Monday, August 12th. The stock was bought at an average cost of $16.33 per share, with a total value of $400,607.56. Following the completion of the acquisition, the chief financial officer now owns 24,532 shares of the company’s stock, valued at $400,607.56. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 1.30% of the stock is owned by insiders.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently added to or reduced their stakes in NVST. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Envista in the third quarter valued at approximately $31,000. GAMMA Investing LLC lifted its position in shares of Envista by 69.8% during the 3rd quarter. GAMMA Investing LLC now owns 1,766 shares of the company’s stock valued at $35,000 after buying an additional 726 shares in the last quarter. Huntington National Bank lifted its position in shares of Envista by 97.8% during the 3rd quarter. Huntington National Bank now owns 1,919 shares of the company’s stock valued at $38,000 after buying an additional 949 shares in the last quarter. Blue Trust Inc. grew its stake in Envista by 69.7% in the 3rd quarter. Blue Trust Inc. now owns 1,957 shares of the company’s stock valued at $39,000 after acquiring an additional 804 shares during the period. Finally, Allspring Global Investments Holdings LLC increased its holdings in Envista by 50.8% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 2,161 shares of the company’s stock worth $43,000 after acquiring an additional 728 shares in the last quarter.
Envista Company Profile
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.
Recommended Stories
- Five stocks we like better than Envista
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Airbnb Stock Attracts Attention With Strong Cash Flow Strategy
- How to Invest in the FAANG Stocks
- MarketBeat Week in Review – 11/4 – 11/8
- How to Effectively Use the MarketBeat Ratings Screener
- Trump’s Return: Which Sectors Will Benefit Most?
Receive News & Ratings for Envista Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envista and related companies with MarketBeat.com's FREE daily email newsletter.